SCHEMBL4816442

SCHEMBL4816442

CC(C)(C)OC(=O)NN=Cc1cccc2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.64
KMT2A Q03164 7/20 0.64
MAPT P10636 3/20 0.64
ALDH1A1 P00352 1/20 0.60
F2 P00734 1/20 0.60
LMNA P02545 1/20 0.60
GCGR P47871 2/20 0.55
MAPK1 P28482 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
MIF P14174 1/20 0.53
RAB9A P51151 5/20 0.53
NPC1 O15118 3/20 0.53
RECQL P46063 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
ATM Q13315 1/20 0.51
POLB P06746 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4816435 1.00 MEN1 (0.64) MEN1KMT2AMAPTALDH1A1F2
SCHEMBL22925015 0.86 ALDH1A1 (0.66) MEN1KMT2AMAPTALDH1A1F2
SCHEMBL15677682 0.82 MEN1 (0.67) MEN1KMT2AMAPTMAPK1TDP1
SCHEMBL27178064 0.80 ALDH1A1 (0.69) MEN1KMT2AMAPTALDH1A1F2
SCHEMBL22925029 0.80 ALDH1A1 (0.69) MEN1KMT2AMAPTALDH1A1F2
SCHEMBL30826048 0.80 ALDH1A1 (0.69) MEN1KMT2AMAPTALDH1A1F2
SCHEMBL14938489 0.80 ALDH1A1 (0.58) MEN1KMT2AMAPTALDH1A1F2
SCHEMBL31309757 0.80 MAPT (0.59) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL23081599 0.78 MAPT (0.54) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL30525756 0.78 MAPT (0.54) MEN1KMT2AMAPTALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432262-B2 Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-10-07 US disclosed
US-7393847-B2 Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) 2008-07-01 US disclosed
US-20070142383-A1 Imidazopyridazinediones, Their Preparation And Their Use As Pharmaceutical Compositions ECKHARDT MATTHIAS 2007-06-21 US disclosed
US-20050203095-A1 Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142383-A1 Imidazopyridazinediones, Their Preparation And Their Use As Pharmaceutical Compositions DPP4, DPP3, DPP7 MEN1 3229/4885KMT2A 2979/4885MAPT 309/4885
US-20050203095-A1 Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions DPP4, DPP3, DPP7 MEN1 3245/4885KMT2A 2943/4885MAPT 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.